CNNMoney.com reports that GlaxoSmithKline is likely to hold its throne as the king of the $25 billion market for respiratory drugs for this season and years to come, despite growing competition and controversy. GlaxoSmithKline's top earner, its Advair asthma inhaler franchise, is expected to remain the leading drug in the respiratory market.